VIGL - Vigil Neuroscience - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

86.38M

Cash

101.6M

Avg Qtr Burn

-17.51M

Short % of Float

6.56%

Insider Ownership

9.10%

Institutional Own.

88.71%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Iluzanebart (VGL101) Details Adult onset leukoencephalopathy w/ axonal spheroids & pigmented glia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VG-3927 (TREM2 agonist) Details Neurodegenerative disease, Alzheimer's disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.